6UJQ image
Entry Detail
PDB ID:
6UJQ
Keywords:
Title:
HHAT Wild Type Peptide KQWLVWLLL Presented by HLA-A206
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2019-10-03
Release Date:
2020-08-19
Method Details:
Experimental Method:
Resolution:
2.55 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:MHC class I antigen
Chain IDs:A
Chain Length:276
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Beta-2-microglobulin
Chain IDs:B
Chain Length:100
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Protein-cysteine N-palmitoyltransferase HHAT
Chain IDs:C
Chain Length:9
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structural dissimilarity from self drives neoepitope escape from immune tolerance.
Nat.Chem.Biol. 16 1269 1276 (2020)
PMID: 32807968 DOI: 10.1038/s41589-020-0610-1

Abstact

T-cell recognition of peptides incorporating nonsynonymous mutations, or neoepitopes, is a cornerstone of tumor immunity and forms the basis of new immunotherapy approaches including personalized cancer vaccines. Yet as they are derived from self-peptides, the means through which immunogenic neoepitopes overcome immune self-tolerance are often unclear. Here we show that a point mutation in a non-major histocompatibility complex anchor position induces structural and dynamic changes in an immunologically active ovarian cancer neoepitope. The changes pre-organize the peptide into a conformation optimal for recognition by a neoepitope-specific T-cell receptor, allowing the receptor to bind the neoepitope with high affinity and deliver potent T-cell signals. Our results emphasize the importance of structural and physical changes relative to self in neoepitope immunogenicity. Considered broadly, these findings can help explain some of the difficulties in identifying immunogenic neoepitopes from sequence alone and provide guidance for developing novel, neoepitope-based personalized therapies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures